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Chronic obstructive pulmonary disease (COPD) is a progressive 
disease of the lung characterized by inflammation, largely irrevers-
ible airflow obstruction, and permanent alveolar enlargement (1). 
COPD afflicts more than 12 million adults and is the fourth lead-
ing cause of death in the United States. Further increases in preva-
lence of and mortality caused by COPD are predicted in the coming 
decades (1, 2). Currently, questions remain about the pathophysi-
ological mechanisms controlling COPD, and, despite numerous 
clinical trials, therapy is limited mainly to supportive measures.
A prominent mechanism of airflow obstruction in COPD is 
emphysema. Emphysema is characterized by the permanent 
enlargement of airspaces accompanied by the loss of elastic recoil 
of the lung. The pathogenesis of the destruction of the alveolar 
unit in emphysema is complex and incompletely understood, 
but is thought to involve chronic inflammation, leukocyte acti-
vation, oxidative stress, and increased elastolytic potential in the 
lung (3). Increased numbers of macrophages, neutrophils, and 
lymphocytes in the airways, parenchyma, and vasculature charac-
terize the inflammation. Macrophages and neutrophils are well 
studied and seemingly contribute to tissue destruction through 
the liberation of extracellular matrix–degrading proteinases (3). 
A potential role for lymphocytes in COPD pathology is becom-
ing increasingly appreciated (4–6). However, mechanistic data in 
support of causal role for lymphocytes in the development or pro-
gression of COPD are limited.
Cells undergoing physical or chemical stress are removed in 
order to control inflammation and promote repair. Multiple 
mechanisms for the detection and elimination of cells undergo-
ing stress have been described previously (7). One system that 
may provide a mechanistic link between epithelial cell stress 
caused by cigarette smoking and immune cell activation in the 
lung involves NK cell group 2D (NKG2D; also known as KLRK1) 
receptor activation. The NKG2D receptor is expressed on circu-
lating and tissue lymphocytes and directly recognizes stressed 
cells through ligands expressed on the cell surface (8). NKG2D 
receptors are expressed almost exclusively on CTLs (i.e., CD8+ 
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T cells, NK cells, NK T cells, and γδ+ T cells) and can directly 
induce cell cytolysis, enhance innate immune functions, and 
modulate adaptive immune responses. The role of this system 
in triggering immune responses might also influence pathways 
that can result in aberrant activation of the immune system, lead-
ing to autoimmunity or other forms of immunopathology (9). 
NKG2D ligands are not expressed in healthy adult tissues, but 
are induced by infection, transformation, and DNA damage (8, 
10–14). Multiple families of structurally distinct NKG2D ligands 
have been identified in both humans and mice. Two families of 
NKG2D ligands have been identified in humans: the MHC class I 
chain-related (MIC) molecules MICA and MICB (15) and the 
UL-16 binding proteins (16–18). Ligands for the mouse NKG2D 
receptor are encoded by the retinoic acid–inducible early genes 
(Raet1a–Raet1e) (19), H60 (20), and Mult1 (21).
Recently, we demonstrated that NKG2D ligand expression is 
induced on pulmonary epithelial cells in response to oxidative 
stress and infection (22, 23), implicating NKG2D receptor activa-
tion as a mechanistic link between epithelial cell stress and lym-
phocyte activation in pulmonary tissues. In this study, we provide 
support for the hypothesis that persistent NKG2D-mediated 
activation of lymphocytes contributes to tissue remodeling and 
emphysema. In particular, we demonstrate that cigarette smoke 
induced NKG2D ligands on pulmonary epithelial cells and that 
NKG2D receptors governed cell-mediated cytotoxicity against cig-
arette smoke–exposed epithelial cells. We also show that sustained 
NKG2D activation was sufficient to cause pulmonary emphysema 
using a transgenic mouse model, which we believe to be novel, that 
regulates the exogenous expression of NKG2D ligands on pulmo-
nary epithelial cells. Moreover, persistent epithelial expression of 
NKG2D ligands in mouse models of cigarette smoke–induced 
COPD and a population of COPD patients strongly correlated 
with morphological and physiological evidence of disease.
Results
Cigarette smoke induces NKG2D ligands in mouse pulmonary epithelium. 
Long-term exposure to cigarette smoke is the primary cause of 
COPD and, specifically, emphysema. We first examined whether 
cigarette smoke exposure induced expression of the mouse NKG2D 
ligand retinoic acid early transcript 1 (RAET1) in a mouse model 
of emphysema. Immunohistochemical analyses demonstrated 
that cigarette smoke exposure for 6 mo induced sustained RAET1 
Figure 1
NKG2D ligands are induced on pulmo-
nary epithelial cells in cigarette smoke–
induced emphysema and mediate CTL 
activation. (A–D) RAET1 was assessed 
by immunohistochemistry in the alveolar 
and airway epithelium of mice exposed to 
filtered air (control; A and C) or cigarette 
smoke (B and D) for 6 mo. Arrows denote 
RAET1+ cells. Scale bars: 50 μm (A and B); 
100 μm (C and D). (E–G) Alveolar epithelial 
tissue sections of mice exposed to cigarette 
smoke were stained for pro-SPC (blue; E), 
RAET1 (red; F), or both (purple; G). Arrows 
indicate alveolar epithelial cells. Photomi-
crographs in A–G are representative of 5 
mice per group. Original magnification, 
×400. (H) Primary mouse type II alveolar 
epithelial cells were isolated as described 
in Methods and treated with CSE or PBS 
for 24 h. RAET1 expression was assessed 
by flow cytometry, and fold increase was 
derived from mean fluorescence intensity 
values. (I) Specific lysis of CSE-treated 
alveolar epithelial cells (1 × 104 cells). 
Cells were cocultured with freshly isolated, 
strain-matched lymphocytes at the indicat-
ed ratios. Shown are PBS-treated epithelial 
cells, 3% CSE-treated cells, and 3% CSE-
treated cells cocultured with lymphocytes 
treated with a monoclonal blocking anti-
body against the mouse NKG2D receptor. 
Data are results of 3 independent experi-
ments performed in quadruplicate.
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expression in both airway epithelium and alveolar epithelium (Fig-
ure 1, A–D). We confirmed the expression of RAET1 on alveolar 
epithelial cells by dual labeling with the type II alveolar epithelial 
cell–specific marker pro-SPC (Figure 1, E–G).
RAET1 expression coincided with the development of emphy-
sema, as determined by increased alveolar diameter. In contrast, 
RAET1 expression was not observed in control mice exposed to 
filtered air only. Quantitation of both RAET1 expression and 
increased alveolar diameter are presented below. Examination of 
NKG2D receptor expression in the lung revealed that approximately 
20% of resident pulmonary lymphocytes express the NKG2D 
receptor (data not shown). This represents a substantial effector 
population, as lymphocytes accounted for about 2 × 105 to 5 × 105 
cells in the mouse lung, and indicates that ligand upregulation is 
the limiting factor in this pathway.
To examine whether cigarette smoke exposure directly induces 
NKG2D ligand expression on pulmonary epithelial cells, we 
exposed primary mouse type II alveolar epithelial cells to cigarette 
smoke extract (CSE) and assessed RAET1 surface levels by flow 
cytometry. Untreated epithelial cells exhibited negligible expres-
sion of RAET1 ligands. However, similar to in vivo effects, CSE 
induced RAET1 surface expression (Figure 1H).
NKG2D ligand induction on alveolar epithelial cells activates CTLs 
in vitro. To assess the functional significance of NKG2D ligand 
induction in response to cigarette smoke, we established a cocul-
ture system using mouse type II cells and syngeneic lymphocytes. 
CSE-treated epithelial cells elicited marked CTL activation com-
pared with PBS-treated epithelial cells, as measured by specific 
lysis of epithelial cells (Figure 1I). To define the contribution of 
ligands for the NKG2D receptor in epithelial cell cytotoxicity, we 
preincubated the lymphocytes with a blocking antibody against 
the mouse NKG2D receptor prior to coculture with CSE-treated 
epithelial cells. Importantly, blocking NKG2D function reduced 
the cytolytic activity toward CSE-treated epithelial cells by approxi-
mately 50%. These findings indicate that NKG2D ligand induction 
on alveolar epithelial cells is a major determinant of CTL activa-
tion after cigarette smoke exposure.
Transgenic overexpression of NKG2D ligands induces pulmonary emphy-
sema. To characterize the response elicited by NKG2D ligands and 
their function in pulmonary pathophysiology, we generated a 
transgenic mouse model that allowed for the conditional expres-
sion of Raet1a in pulmonary epithelial cells. We expressed Raet1a 
in pulmonary epithelial cells under the control of doxycycline 
(DOX) administration using the ccsp-rtTA transgenic system pre-
viously described (24). We established 3 separate Raet1a Tg mouse 
lines (lines 20, 22, and 32) bearing the target (TetO)7-CMV-Raet1a 
transgene. Line 20 Raet1a Tg mice failed to demonstrate Raet1a 
transcript induction after DOX administration. Line 32 Raet1a Tg 
mice demonstrated modest Raet1a transcript induction. Line 22 
Raet1a Tg mice exhibited robust Raet1a transcript induction and 
were used in all subsequent studies unless otherwise indicated. 
Immunohistochemical staining of DOX-treated Raet1a Tg mice 
confirmed RAET1 expression throughout the airway and alveo-
lar epithelium (Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI34462DS1) (25). 
None of the bitransgenic mice expressed the Raet1a transgene in 
the absence of DOX. Additionally, none of the bitransgenic mice 
exhibited any lung pathologies in the absence of DOX.
We first examined whether NKG2D ligand expression affected 
the composition of pulmonary leukocyte populations. Our data 
showed that RAET1 expression did not alter lung lymphocyte 
composition (CD3+, CD4+, CD8+, γδ+, and NK cells) or the percent-
age of NKG2D+ lymphocytes (Figure 2A). Similarly, total and dif-
ferential bronchoalveolar lavage (BAL) macrophage, neutrophil, 
and lymphocyte counts were not significantly different from those 
of control mice (P > 0.6 for all comparisons; Figure 2A).
Histological examination of the lungs of Raet1a Tg mice after 
DOX administration revealed that RAET1 expression caused a 
progressive destruction of the alveolar architecture, resembling 
pulmonary emphysema (Figure 2, B and C). Quantitation of the 
changes in airspace enlargement, as assessed by alveolar diame-
ter, demonstrated a nearly 300% increase in airspace enlargement 
compared with control-treated transgenic mice. Tissue remodel-
ing was primarily localized to the alveolar architecture, with mod-
erate alterations of the epithelium in the terminal airways, after 
60 d DOX administration (data not shown). Consistent with the 
development of an emphysematous phenotype, we also observed 
increased static and dynamic compliance, physiological parameters 
describing the loss of elastic recoil and lung distensibility (Figure 
2, D and E). Similarly, pressure-volume curve analysis illustrated a 
loss of lung elasticity in Raet1a Tg mice (Figure 2F).
We next examined whether the NKG2D receptor specifically 
mediated the effects of RAET1 expression by administering an anti-
NKG2D blocking antibody to Raet1a Tg mice. We found that block-
ing NKG2D receptor activation completely abrogated the alveo-
lar destruction observed in transgenic mice (Figure 2, B and G). 
These data strongly suggest that alveolar destruction, as a conse-
quence of RAET1 expression, is mediated exclusively through the 
NKG2D receptor. Furthermore, we assessed the relative contribu-
tions of lymphocyte subpopulations to the alveolar destruction 
observed in Raet1a Tg mice. Elimination of NK cells using in vivo 
antibody depletion (anti–asialo GM1) significantly abated the 
effects of RAET1 expression in this mouse model (Figure 2G). In 
contrast, depletion of CD4+, CD8+, αβ+, and γδ+ T cells had no sig-
nificant effects on the development of airspace enlargement.
Transgenic overexpression of NKG2D ligands induces epithelial cell apop-
tosis and CTL activation, but not inflammation. Because NKG2D recep-
tor activation can initiate several responses including inflamma-
tion, modulation of the adaptive immune response, and apoptosis 
of NKG2D ligand–expressing cells (8), we next sought to examine 
the possible contributions of these mechanisms to RAET1-induced 
emphysema. Assessments of bioactivity of the apoptotic markers 
active caspase 3 (Casp3) and Casp3/7 revealed that the apoptosis 
signals in the lungs of Raet1a Tg mice were increased (Figure 3, 
A and B). Immunohistochemistry revealed that the active Casp3+ 
cells primarily localized to the alveolar compartments, consistent 
with the emphysematous phenotype. We assessed CTL activation 
by measuring the apoptotic effector enzyme granzyme B. Consis-
tent with a role in CTL activation during epithelial cell apoptosis, 
we observed increased granzyme B protein levels in Raet1a Tg lungs 
both before and during the development of alveolar destruction 
(Figure 3C). These data are consistent with the results obtained 
with cigarette smoke–induced NKG2D ligand induction and CTL 
activation. That is, induction of NKG2D ligands activates the 
pulmonary immune system and leads to the destruction and/or 
removal of pulmonary epithelial cells.
Because MMPs are thought to play a critical role in the develop-
ment of emphysematous lesions in mouse models (26), we assessed 
the activation state of the pulmonary macrophage compartment 
by examining MMP2 and MMP9 activation by gelatin zymography. 
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Figure 2
In Raet1a Tg mice, inducible expression of RAET1 on pulmonary epithelial cells leads 
to pulmonary emphysema. (A) Lymphocyte populations in digested whole lungs of 
mice given DOX for the indicated times were quantitated by flow cytometry using 
antibodies specific for the indicated cell surface markers. Data are results of 3 inde-
pendent experiments using pooled samples from at least 3 mice per group. Inflam-
matory cells in the lung were assessed by enumeration of cell differentials in the BAL 
(n = 5 per group). (B) H&E-stained lung sections from mice that were left untreated, 
administered DOX for 5, 15, 30, and 60 d, or administered 30 d DOX concurrently 
with an NKG2D blocking antibody. Photomicrographs are representative of 5 mice per 
group. Scale bar: 100 μm. (C) Time course of alveolar destruction, quantified as mean 
linear intercept. (D–F) Mice were administered DOX for 60 d, and static compliance 
(D), dynamic compliance (E), and pressure-volume loops (F) were determined using 
a forced oscillation technique. These functional indicators of elastic recoil loss reflect 
the ease with which the lung distends. Values are mean ± SD (n = 3–5 per group). (G) 
Specificity for NKG2D-mediated effects (n = 5 per group). Lymphocyte populations 
were specifically depleted as described in Methods, and mean linear intercept was 
assessed after 30 d DOX treatment. *P < 0.05 versus respective no DOX control.
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Raet1a Tg mice failed to demonstrate an increase in MMP2/9 activ-
ity, which coincided with the development of airspace enlargement 
(Figure 3D). Additionally, we measured the transcript levels of 
Mmp12, Mmp14, tissue inhibitor of metalloproteinases 1 (Timp1), 
and Timp3. Raet1a Tg mice failed to demonstrate an increase in 
these mediators, coinciding with the development of airspace 
enlargement (Figure 3E). Together, these data indicate that trans-
genic expression of RAET1 does not result in perturbations of 
the lymphocyte or macrophage populations known to contribute 
to airspace enlargement in smoke-induced emphysema models. 
Additionally, the lack of any effects on cell composition in these 
compartments, along with the data demonstrating activation of 
CTLs (i.e., granzyme B), suggests that the mechanism of alveolar 
destruction involves the efficient removal of affected cells without 
leading to collateral effects (i.e., inflammation).
Sustained RAET1 expression correlates with increased alveolar destruc-
tion in multiple models of pulmonary emphysema. To identify whether 
there is a relationship between the persistent expression of RAET1 
and the development of airspace enlargement, we measured these 
endpoints in multiple models of airspace enlargement (Figure 4). 
These models included Raet1a Tg lines (strain FVBN background), 
mice exposed to cigarette smoke (strain BALBc/J), and a model 
of acrolein-induced COPD (strain C57BL/6J) that we recently 
described (27). These data illustrate that there is a dose response 
relationship between the number of RAET1+ epithelial cells and 
the degree of airspace enlargement (r2 = 0.96, P = 0.001).
NKG2D ligand expression increases in the peripheral lung of COPD 
patients and is associated with the development of COPD pathologies. To 
further investigate the potential role of NKG2D in COPD, we 
examined the pulmonary expression of an NKG2D ligand, MICA, 
in human subjects with and without disease and assessed its asso-
ciation with several clinical components of the disease. Immu-
noblot analysis from peripheral lung resections demonstrated 
that protein levels of MICA were significantly increased in COPD 
patients (Figure 5, A and B). MICA expression was not detected in 
liver specimens from patients, regardless of COPD diagnosis (data 
not shown), which suggests that MICA upregulation is not a ubiq-
uitous feature in tissues obtained from COPD patients.
Because cytotoxic CD8+ and NK lymphocytes and their func-
tional proteases are localized to the small airways (28) and to the 
lung parenchyma (29), we quantitated the abundance of T cell 
subpopulations, NK cells (CD56+), and NKG2D+ cells in periph-
eral lung tissue of non-COPD and COPD patients undergoing 
thoracic surgery. Flow cytometric analyses indicated that NKG2D 
receptors were expressed on greater than 50% of peripheral lung 
lymphocytes (Figure 6A). However, the percent of NKG2D+ cells 
Figure 3
Transgenic overexpression of NKG2D 
ligands induces epithelial cell apoptosis 
and CTL activation. (A) Effector caspase 
expression in lungs of Raet1a Tg mice 
administered 30 d DOX was assessed 
by Casp3/7 bioactivity in whole lung 
homogenates (n = 5 per group). (B) 
Apoptotic cell accumulation in the lungs 
was assessed by immunohistochemistry 
on paraffin-embedded sections using a 
rabbit antibody specific for active Casp3. 
The number of active Casp3+–stained 
cells was quantified from photomicro-
graphs of lung sections and presented 
as mean ± SD cells per high-power field 
(hpf). (C) CTL effector function was 
induced by NKG2D ligand expression in 
vivo. Western blot analysis on whole lung 
homogenates using a granzyme B–spe-
cific antibody showed increased protein 
expression after NKG2D ligand induction 
in pulmonary epithelial cells. (D) MMP2 
and MMP9 activity were not altered in 
the lungs of mice ectopically expressing 
RAET1. Gelatin zymography was con-
ducted on lung homogenates of Raet1a 
Tg mice left untreated (n = 2) or treated 
with 30 d DOX (n = 3). Photomicrograph 
is representative of results obtained from 
4–6 mice per group. (E) Transcript levels for 
MMP inhibitors Mmp12 and Mmp14 were 
not altered in the lungs of mice ectopically 
expressing RAET1. Real-time quantitative 
PCR was performed on RNA isolated from 
the lungs of Raet1a Tg mice left untreated 
or treated with 30 d DOX (n = 5 per group). 
*P < 0.05 versus no DOX control.
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was not different between groups (Figure 6B). In addition, NK 
cells, which universally express NKG2D (8), represented greater 
than 30% of the peripheral lung lymphocyte population. Pheno-
typing of CD3+ T cells showed that greater than 90% of cytotoxic 
CD8+ T cells were NKG2D+, whereas fewer than 5% of CD4+ T cells 
expressed NKG2D (Figure 6, C–E).
To further examine the relationship between NKG2D ligand 
expression and the development of COPD pathologies, we assessed 
MICA expression in bronchial biopsies from 93 patients (21 never 
smokers, 30 former smokers, and 42 current smokers). These 
patients were extensively characterized in terms of pulmonary 
function, lung cancer staging, and presence of bacteria in broncho-
aspirate cultures. MICA staining in bronchial biopsies from cur-
rent and former smokers was present in the apical and basolateral 
membranes as well as airway epithelial cell cytoplasm (Figure 7, 
A–H). Analysis of MICA expression in the alveolar unit revealed a 
more diffuse pattern, possibly reflecting the expression in vascular 
endothelium (Figure 7I). Risk estimations indicated that sex, ciga-
rette smoking, chronic bronchitis symptoms, and COPD diagnosis 
were all strongly associated with MICA expression in the airway 
epithelium (Table 1; see Methods and Supplemental Figure 2 for 
delineation of MICA+ and MICA– categorical variables). The forced 
expiratory volume in the first second, a marker of airflow obstruc-
tion, and the lung transfer capacity for CO (TLCO), a marker of 
pulmonary emphysema, were significantly decreased in MICA+ 
patients (Table 1). Moreover, macroscopic evidence of emphysema 
of the lungs, evident in 21 (23%) of the patients with an available CT 
scan of the lungs (n = 87), was associated with decrease of TLCO (evi-
dent emphysema, 67 ± 14; versus nonevident emphysema, 83 ± 22; 
P = 0.009), CO transfer coefficient (KCO, equal to TLCO normalized 
to effective alveolar volume; 75 ± 13 versus 92 ± 19; P = 0.001), and 
BMI (22 ± 5 versus 26 ± 3; P = 0.01). A near significant association 
was found between definite macroscopic emphysema and expres-
sion of MICA (P = 0.07). MICA expression associated with the pres-
ence of lung cancer, but not with other variables, including age, 
cancer staging, or evidence of bacterial infection (Table 1).
Although endobronchial biopsies are not the target tissue in 
regard to the development of emphysema, we evaluated these 
specimens for several reasons. COPD is a complex mixture of both 
pulmonary emphysema and chronic bronchitis, and it is reason-
able to assume that changes in the airways of patients with COPD 
are reflective and predictive of changes in the peripheral lung (30). 
Moreover, we could obtain reasonable access to endobronchial 
biopsies, as opposed to the peripheral lung, in larger study patient 
groups. Therefore, we examined biopsies of peripheral lung tissues 
available in the limited subgroup of COPD cases and non-COPD 
controls that were submitted to thoracic surgery (n = 17). All sam-
ples that demonstrated MICA+ endobronchial biopsies (n = 6) were 
also MICA+ in the alveolar epithelium.
Discussion
A potential role for lymphocytes in COPD pathologies is based pri-
marily on reports demonstrating that the number of lymphocytes 
in the lung correlates with the extent of COPD clinical endpoints 
(31–34). However, the mechanism whereby lymphocytes become 
activated and contribute to COPD pathologies remains unclear. 
In the present study, we provide evidence, which we believe to 
be novel, that a lymphocyte activation pathway, NKG2D ligand 
expression, is associated with COPD pathologies in mouse models 
of disease and in human patients. Furthermore, we demonstrated 
that pulmonary expression of NKG2D ligands is sufficient for the 
development of emphysema in a mouse model.
Figure 4
NKG2D ligand expression on pulmonary epithelial cells correlates with 
increased alveolar diameter in multiple mouse models of emphysema. 
The abundance of RAET1 expression on pulmonary epithelial cells 
was plotted against the increase in alveolar diameter (mean linear 
intercept) compared with respective control mice in 3 experimental 
models of pulmonary emphysema. RAET1 expression and mean lin-
ear intercept were quantified as described in Methods. The statistical 
significance of the relationship between RAET1 and increased alveolar 
diameter in these models is P < 0.001.
Figure 5
MICA protein expression is increased in 
peripheral lung tissue of COPD patients. 
(A) MICA protein levels in peripheral lungs 
of non-COPD and COPD patients were 
assessed by immunoblot analysis. (B) 
Relative expression of individual MICA and 
β-actin bands were quantitated by scanning 
densitometry and expressed as a ratio of 
MICA to β-actin. Values are mean ± SD. 
*P < 0.05 versus non-COPD.
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Based on our experimental findings, we postulate that sus-
tained expression of NKG2D ligands leads to the disruption of 
the alveolar architecture by CTL-mediated apoptosis of pulmo-
nary epithelial cells. Given that NKG2D-bearing cells were abun-
dant in the lung and that NKG2D lymphocyte populations did 
not considerably change in our mouse models of emphysema or 
COPD patients, we conclude that the mechanisms controlling 
this pathway are primarily dependent on the anomalous, sus-
tained expression of NKG2D ligands on pulmonary epithelial 
cells and are independent of NKG2D receptor regulation. Several 
lines of evidence from in vitro and in vivo models demonstrate 
that the NKG2D pathway directly contributes to the pathogen-
esis of COPD. First, we showed that NKG2D ligands were not 
constitutively expressed in pulmonary epithelial cells of healthy 
subjects or naive mice, but cigarette smoke exposure associated 
with NKG2D ligand expression in both airway and peripheral tis-
sues. Second, we showed that cell-mediated cytotoxicity against 
cigarette smoke–exposed alveolar epithelial cells was dependent 
on NKG2D receptor signaling. Third, transgenic expression of 
NKG2D ligands by pulmonary epithelial cells resulted in increased 
apoptosis of epithelial cells and emphysema, which was critically 
dependent on the function of NKG2D and NK cells. Fourth, we 
used multiple mouse models of emphysema to establish a causal 
relationship between NKG2D ligand expression and the typical 
histological changes of emphysema.
The mechanisms regulating NKG2D-mediated effector func-
tions have been thoroughly characterized (reviewed in ref. 35). 
NKG2D engagement is dependent on DAP10/DAP12 adaptor mol-
ecules that recruit Src family kinases and initiate multiple down-
stream signaling pathways that culminate in granule polarization, 
cytokine release, and cytotoxicity. In addition to ligand engage-
ment, the expression and function of NKG2D can be influenced by 
other factors in the immune microenvironment, including IL-15 
(36), IL-21 (37), and TGF-β1 (38). However, the number of effector 
lymphocytes expressing the NKG2D receptor was not affected by 
increased NKG2D ligand expression. Our present study as well as 
previous studies by others (28, 29) demonstrate that CTLs, includ-
ing NKG2D+ lymphocytes, are constitutively present in substan-
tial numbers in the lung parenchyma. The differences in NKG2D 
receptor expression between mouse and human pulmonary lym-
phocytes represent a salient consideration in the interpretation 
of the data presented in the present study. In humans, NKG2D is 
present on the majority of CD8+ T cells and NK cells. In contrast, 
NKG2D is expressed primarily on NK cells, but not CD8+ T cells, 
in mice. Therefore, our data demonstrating that NK cell depletion, 
but not CD8+ T cells, ablated RAET1-mediated alveolar destruc-
Figure 6
NKG2D receptors are constitutively expressed on pulmonary CTLs. (A) NKG2D receptor expression on lymphocytes isolated from peripheral lung 
tissue of a representative COPD patient. Lymphocyte population was defined by forward and side scatter properties. Open histogram represents 
isotype control staining; filled histogram represents anti-NKG2D staining. (B) Relative abundance of CD3+CD4+, CD3+CD8+, CD56+ (NK), and 
NKG2D+ lymphocytes in the peripheral lungs of non-COPD and COPD patients. (C and D) CD4+NKG2D+ T cells (C) and CD8+NKG2D+ T cells 
(D) isolated from peripheral lung tissue of a representative COPD patient gated on CD3+ cells. (E) Relative abundance of CD3+CD4+NKG2D+ and 
CD3+CD8+NKG2D+ T cells in the peripheral lungs of non-COPD and COPD patients. Values are mean ± SD. n = 5 (non-COPD); 10 (COPD).
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tion in the transgenic mouse model may not represent a congruent 
response in human disease. It is more likely that the response to 
NKG2D ligands in humans is also mediated by the effector func-
tions of CD8+ T cells and includes potentially confounding fac-
tors such as concurrent T cell receptor activation and the impact 
of pathogen-based disease exacerbations (39). We conclude that 
induced NKG2D ligand expression, as opposed to receptor expres-
sion, is the major determinant of NKG2D-attributed pathologies 
in COPD. This conclusion is supported by observations that non-
smokers had no MICA expression, but expressed the same propor-
tion of NKG2D+ CTLs, compared with COPD patients. Moreover, 
exogenous RAET1 expression in pulmonary epithelial cells caused 
an emphysematous phenotype without altering the CTL number 
in the parenchyma. Our conclusion is also bolstered by the lack of 
modulation of NKG2D+ cells observed in both cigarette smoke–
exposed mouse lungs and Raet1a Tg mice, and the lack of pulmo-
nary inflammation or macrophage activation (as evidenced by 
MMP activation) observed in mice expressing exogenous RAET1.
The apparent lack of MICA expression in some smokers and 
COPD patients is intriguing. Current paradigms of complex dis-
ease pathogenesis, including COPD, incorporate multiple factors 
and pathways and include the possibility of interactions among 
them. The absence of MICA in a subgroup of smokers and COPD 
patients could be a reflection of several possibilities. These include 
an actual absence of MICA in some patients, attributable to inter-
individual variability in response to exposures inherent to any bio-
logical process; potential anatomical heterogeneity of the MICA 
expression (i.e., a negative biopsy obtained from an anatomical 
location does not exclude MICA expression in other airways); 
expression levels below our detection limits, and the potential 
involvement of other NKG2D ligands, such as ULBP proteins. The 
presence of aberrant polymorphic MICA alleles may circumvent 
detection with the antibody and also contributes to a failure to 
detect MICA expression (40). For example, the MICA-A5.1 allele 
has 1 extra nucleotide in the transmembrane region compared 
with the MICA-A5, which leads to a frame shift. This results in 
Figure 7
MICA expression is associated with the development of COPD. (A–D) 
MICA expression in airway epithelium and alveolar epithelium was 
assessed by immunohistochemistry. Immunofluorescent detection of 
MICA expression in the bronchial epithelium was assessed by confocal 
microscopy in current smokers with COPD (A and B are serial sections 
from same patient to demonstrate isotype control staining reaction), 
never smokers (C), and former smokers with COPD (D). Representa-
tive images are shown. (E–H) Phase contrast images were obtained 
by confocal microscopy using the same settings. (I) MICA localization 
in the alveolar epithelium was assessed by light microscopy in the 
peripheral lung of a current smoker with COPD. Original magnification, 
×40; ×200 (inset in I).
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a premature stop codon within the transmembrane region, and, 
consequently, no cytoplasmic tail is present in these MICA mol-
ecules, which can lead to aberrant expression on the cell surface. 
Furthermore, we cannot exclude the possibility that smokers with-
out a COPD diagnosis that demonstrate MICA expression in the 
epithelium are absolutely free of pulmonary disease. According to 
present definitions, diagnosis of airflow obstruction and COPD 
itself is based on pulmonary function tests, mainly spirometry. 
Nevertheless, several studies demonstrate that high-resolution CT 
is more sensitive and specific than commonly used functional tests 
for the evaluation of initial emphysema in asymptomatic smok-
ers, despite normal or minimal abnormal changes in spirometry, 
TLCO, or other variables (41, 42). In other words, we speculate that 
it is probable that the definition of COPD according to current 
guidelines, and hence assignation of our volunteers to one group, 
could underestimate the presence of early phases or less obstruc-
tive phenotypes of the disease. Additionally, the potential abroga-
tion of bronchial MICA expression in response to chronic inhaled 
treatment may confound the detection of ligand expression, as 
most COPD patients receive inhaled β-adrenergic and inhaled 
steroids that potentially regulate epithelial cell gene expression. 
Finally, interindividual variability in treatment compliance may 
also represent a variable explaining potential MICA downregula-
tion in some COPD patients.
The results of the present study indicate that the progressive alve-
olar destruction observed in Raet1a Tg mice is primarily a conse-
quence of directed cytotoxicity against RAET1+ cells. This response 
was associated with an increase in perforin/granzyme activity that 
was accompanied by an increase in apoptotic pulmonary epithelial 
cells. These results were not surprising, because previous studies 
have demonstrated that exogenous expression of NKG2D ligands 
elicits perforin/granzyme-mediated cytolysis in vitro (43, 44). How-
ever, these findings represent an expansion of earlier studies inves-
tigating the role of CTLs in COPD. Along these lines, increased 
expression of perforin, a pore-forming protein that causes apopto-
sis of target cells via cytolytic granules, has previously been reported 
in CTLs in patients with COPD (45), and increased alveolar epithe-
lial cell apoptosis is correlated with the number of CTLs in patients 
with emphysema (34). In addition, recent studies demonstrate that 
cytotoxic T cells are necessary for the development of toxicant-
induced emphysema in mice (27, 46).
Our findings of no major alterations in the cellular composi-
tion of the BAL or whole lung compartments of Raet1a Tg mice 
coincident with the development of alveolar destruction were 
somewhat unexpected. NKG2D receptor activation in vitro results 
in the elaboration of several cytokines (IFN-γ, TNF-α, IL-2, IL4, 
and GM-CSF; refs. 16, 47), and chemokines (macrophage inflam-
matory protein 1-β and I-309; refs. 16, 48, 49) that are capable of 
inducing the accumulation and activation of multiple leukocyte 
populations. Therefore, the lack of BAL and lung inflammation 
in Raet1a Tg mice suggests that the binding of mouse NKG2D by 
RAET1 in vivo elicits a fundamentally different response than that 
observed in vitro (i.e., inflammatory cytokine elaboration), or that 
these mediators are not produced in sufficient quantities in vivo 
to induce overt inflammation. The implication of these findings 
is that the effector function of RAET1 expression and/or NKG2D 
receptor activation is downstream of both the inflammation and 
excess proteolytic activity observed in the natural progression of 
pulmonary emphysema. It is important to emphasize that this is 
not necessarily the same expectation we would have for the effects 
of endogenous NKG2D ligand expression induced in a toxicant-
induced model of airspace enlargement. In the instance of endog-
enous induction by cigarette smoke exposure, we expect that direct 
effects of the smoke, inflammation, and increased matrix degrada-
tion contribute to the stress imposed on the epithelium, which 
leads to the induction of RAET1 expression. Our present results 
highlight the difficulties of dissecting the cellular and molecular 
mechanisms of a complex disease, but demonstrate that the devel-
opment of an experimental model of reduced complexity can help 
delineate the role of CTLs in COPD pathogenesis.
An important consideration in these studies is that the patholo-
gies are dependent on sustained as opposed to transient expres-
sion of NKG2D ligands in the pulmonary microenvironment. 
Several acute experimental exposures initiate pulmonary NKG2D 
ligand expression in mice in a transient manner, including pul-
Table 1
MICA expression in bronchial epithelium according to demo-
graphic and clinical characteristics
	 	 Total	 MICA–	 MICA+	 P
General	characteristics
	 n 93 56 37
 Sex (male/female) 75/18 40/16 35/2 0.006
 Age (yr) 66 ± 11 67 ± 10 65 ± 11 0.28
Smoking	status
 Never smoker 21 21 0
 Former smoker 30 18 12
 Current smoker 42 17 25 0.000
COPD	and	smokingA
 Non-COPD never smoker 15 15 0
 Non-COPD former smoker 4 4 0
 Non-COPD current smoker 7 2 5 0.004B
 COPD never smoker 6 6 0
 COPD former smoker 26 14 12
 COPD current smoker 35 15 20 0.034C
Chronic	bronchitis
 No 47 37 11
 Yes 46 19 26 0.000
Pulmonary	function
 FEV1 (% predicted) 67 ± 23 71 ± 25 61 ± 19 0.041
 FVC (% predicted) 73 ± 18 77± 20 69 ± 19 0.171
 FEV1/FVC ratio 65 ± 12 66 ± 13 64 ± 10 0.249
 TLC (% predicted) 95 ± 19 97 ± 20 93 ± 19 0.351
 TLCO (% predicted) 78 ± 22 86 ± 22 68 ± 16 0.005
Macroscopic	emphysemaD
 Nonevident 66 43 23
 Evident 21 9 12 0.070
Lung	cancer
 Negative 31 25 6
 Positive 62 31 31 0.004
Bronchoaspirate	cultureE
 Negative 58 35 23
 Positive 35 21 14 0.974
Age and pulmonary function values are mean ± SD; other values denote n.  
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; TLC, 
total lung capacity. AP = 0.000, non-COPD versus COPD groups. 
BAmong smoking statuses in non-COPD group. CAmong smoking sta-
tuses in COPD group. DAs assessed by CT scan; 6 scans were not avail-
able. EBacteria species included S. flora, P. aeruginosa, H. influenza,  
S. pneumoniae, S. aureus, S. marcescens, and M. tuberculosis.
Downloaded on August 16, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/34462
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 3   March 2009 645
monary bacterial infection (23) and exposure to pulmonary 
irritants (e.g., ozone and acrolein; M.T. Borchers, unpublished 
observation). Similar to in vitro studies with human pulmonary 
epithelial cells (22), acute exposures lead to maximal induction 
of NKG2D ligand expression at 24–48 h that rapidly returns to 
baseline. Under all the above-described conditions, acute expres-
sion of NKG2D ligands does not lead to irreversible changes in the 
pulmonary architecture. However, the present study demonstrated 
that inducible, sustained expression of NKG2D ligands in mice 
occurred following chronic exposure to cigarette smoke and that 
sustained pulmonary expression of NKG2D ligands in the Raet1a 
Tg mouse model was sufficient to cause pulmonary emphysema. 
More importantly, we demonstrated that upregulation of NKG2D 
ligands in COPD patients was likewise persistent, as evidenced by 
the lack of association between MICA upregulation and either 
infection or smoking status. These data also demonstrate the 
importance of determining whether NKG2D pathway blockade 
is effective in attenuating experimental emphysema development 
induced by cigarette smoke.
The immune system can be activated by signals from cells 
exposed to pathogens, environmental stimuli, or mechanical 
damage. The presumed function of stress immunosurveillance 
is to contribute to tissue repair and maintenance by eliminat-
ing stressed or damaged cells and to facilitate the restoration of 
healthy cells (7, 50). In the context of COPD, the local pulmonary 
immune system appears to be chronically responding as if it rec-
ognizes a tumor cell or virus-infected cell. Although CTL activa-
tion in response to tumors and pathogens is highly beneficial to 
the host, the CTL response to chemically stressed cells (e.g., ciga-
rette smoking) is ultimately detrimental to the susceptible host 
as it contributes to the imbalance in tissue injury/repair that is 
a pathognomonic feature of COPD. Previously, we reported that 
cultured human airway epithelial cells respond to acute oxidative 
stress by transiently expressing several known ligands for NKG2D 
(22). Although the present study did not address the mechanisms 
of NKG2D ligand induction on pulmonary cells, we presume that 
it is likely a combination of direct effects of the many toxicants 
present in cigarette smoke and the indirect effects of products of 
tissue damage. Along these lines, NKG2D ligand induction has 
previously been reported in response to toll-like receptor stimula-
tion (51) and DNA damage (10). In this context, NKG2D ligand 
induction represents a general mechanism of immune cell activa-
tion used by the lung under stress.
We provide the first evidence to our knowledge that the NKG2D 
pathway is associated with COPD, particularly the morphological 
and/or physiological endpoints of emphysema. We demonstrated 
that in multiple mouse models of emphysema, RAET1 expression 
was strongly associated with the development of airspace enlarge-
ment. In human COPD patients, bronchial biopsies demonstrated 
that MICA staining was associated with cigarette smoking and 
emphysema development. Similarly, MICA expression increased 
in peripheral lung tissue from a separate COPD patient popula-
tion. Investigators have hypothesized that COPD represents an 
autoimmune disease and suggested that aberrant activation of 
the immune system accounts for the findings that inflammation 
persists and lung function continues to decline in former smokers 
(52, 53). Several findings support the concept that autoimmune 
reactions accompany COPD pathogenesis. Oligoclonal expansions 
of CD4+ T cells in emphysematous lung tissue of patients under-
going thoracic surgery have been reported (54), but these find-
ings may reflect the response to current infection or tumor. More 
recently, we have demonstrated clonal expansions in predomi-
nantly CD8+ T cells in a mouse model of COPD devoid of infec-
tions or tumors (55). Direct evidence of autoimmunity is provided 
by the reports that circulating antibodies against elastin fragments 
correlate with emphysema severity (56) and that autoantibodies 
against pulmonary epithelial cells are present in COPD patients 
(57). Our present findings support the hypothesis that persistent 
NKG2D ligand expression on pulmonary epithelial cells, and the 
subsequent pathological consequences, is a form of autoimmu-
nity because it reflects a breakdown in self tolerance. The emerg-
ing picture is that immunopathogenesis represents an important 
component of COPD progression.
Presently, it is unknown whether activation of the NKG2D path-
way contributes to other chronic pulmonary diseases, or whether 
other exposures (e.g., passive exposure to cigarette smoke or other 
inhaled pollutants or viral infections), if any, are also associated 
with aberrant MICA expression in the lung. However, the poten-
tial pathogenic role of current or former active smoking is high-
lighted in the present study, as MICA was associated with smok-
ing whereas it was not detected in any bronchial sample obtained 
from the limited number of patients with nonsmoking COPD 
or in former smokers without COPD. In addition, examination 
of a limited number of never smoker asthma patients failed to 
reveal any MICA immunoreactivity in bronchial biopsy material 
(data not shown). There was no a priori evidence that any immune 
functions are disease specific. Indistinguishable lymphocyte effec-
tor functions are triggered in response to pathogens, cancer, and 
autoimmune reactions. Therefore, the consequences of NKG2D 
ligand expression are likely dependent on temporal and spatial 
expression (airway versus alveoli) and the context of the unique 
pulmonary immune microenvironment.
In summary, our findings that NKG2D mediated CTL activation 
after exposure to cigarette smoke, that NKG2D ligand expression 
caused emphysema in transgenic mice, and that NKG2D ligands 
were aberrantly expressed in the pulmonary epithelium of both 
animal models and patients with COPD, which coincided with 
emphysema development, provide mechanistic insight into COPD 
pathogenesis. These data provide a more comprehensive picture 
of COPD and increase our understanding of the effects of current 
treatments and new therapeutics developed for COPD patients. 
Moreover, we demonstrated that anti-NKG2D blocking anti-
body abrogated emphysema development in the animal model, 
which suggests the NKG2D pathway maybe a molecular target for 
complementary treatment and/or prevention of emphysema. An 
increased understanding of how the pulmonary epithelium com-
municates with the immune system in order to maintain healthy 
tissue will provide the foundation for future investigations to 
determine the role of lymphocyte subpopulations in pulmonary 
diseases in which injury and repair are in disequilibrium.
Methods
Mice. All procedures were conducted using mice 8–12 wk of age maintained 
in ventilated microisolator cages housed in an American Association for 
Accreditation of Laboratory Animal Care–accredited animal facility. Proto-
cols and studies involving animals were conducted in accordance with NIH 
guidelines and were approved by the Institutional Animal Care and Use 
Committee of the University of Cincinnati College of Medicine.
Animal exposures. Mice (8-wk-old female BALB/CJ; The Jackson Labora-
tory) were exposed to filtered air or 150 mg/m3 cigarette smoke from stan-
Downloaded on August 16, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/34462
research article
646	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 3   March 2009
dard research cigarettes (2R4F; University of Kentucky Tobacco Research 
and Development Center) — 4 h per d, 5 d per wk — for 6 mo using the 
Teague TE-10Z whole body exposure system (Teague Enterprises). Mice 
(8-wk-old female C57BL/6J; The Jackson Laboratory) were exposed to fil-
tered air or 2.0 ppm acrolein — 6 h per d, 5 d per wk — for up to 12 wk as 
previously described (58) to induce the hallmark features of COPD.
Immunohistochemistry. RAET1 immunohistochemistry was performed 
on formalin-fixed, paraffin-embedded mouse lung tissue with a goat 
polyclonal antibody (clone AF1136; R&D Systems) as previously described 
(23). Pro-SPC was detected with a rabbit polyclonal antibody (Chemicon). 
RAET1 and pro-SPC dual labeling was visualized using alkaline phos-
phate–labeled secondary antibody kits (Vectastain ABC-AP kit; Vector 
Laboratories) with Vector Red and Vector Blue Alkaline Phosphate Sub-
strate kits (Vector Laboratories) according to manufacturer’s recommen-
dations. Activated Casp3 protein was detected with a rabbit polyclonal 
antibody (R&D Systems) in 5-μm paraffin sections of mouse lung tissue 
as previously described (27). RAET1+ and Casp3+ cells were quantitated as 
the number of positive cells per randomly chosen high-power field (×400 
magnification) of 5 fields per section from 3 sections per mouse (n = 5–8 
mice per group).
MICA immunoreactivity was assessed using a mouse anti-human MICA-β1 
monoclonal antibody (clone AMO1; Immatics Biotechnologies) as described 
in Supplemental Figure 2. Both immunofluorescence and immunoperoxi-
dase techniques were similarly performed on adjacent sections using FITC-
conjugated and peroxidase-conjugated anti-mouse secondary antibodies 
(BD Biosciences — Pharmingen). Confocal microscopy was performed using 
a Leica SP2 confocal scanning laser microscope adapted to an inverted Leica 
DM IRBE microscope. Immunoreactivity was assessed on peroxidase-stained 
sections using a single-blind approach by 3 investigators and was expressed 
as a binomial categorical variable, MICA– or MICA+. MICA+ was defined 
using 2 objective criteria obtained from a computer-assisted image analysis 
based on epithelial staining: the hue and saturation of the reaction, and the 
stained area fraction (see Supplemental Figure 2).
Isolation of mouse alveolar epithelial cells and flow cytometry. Primary alveolar 
epithelial cells were isolated and maintained as previously reported (59). 
Lungs were perfused with 10 ml of 0.9% saline through the right ventricle, 
and 3 ml Dispase (Fisher) was instilled through a cannula in the trachea, 
followed by 1 ml of 1% low melt agarose (Promega). After a 2-min incuba-
tion of the animal on ice to harden the agarose, the lungs were removed 
and incubated separately in 1 ml Dispase for 45 min at room temperature. 
Lungs were then placed in 60-mm culture dishes containing 7 ml DMEM 
(Mediatech), 20 mM HEPES (Fisher), 100 U/ml penicillin-streptomycin 
(Invitrogen), and 100 U/ml DNAse I (Sigma-Aldrich). The lungs were gen-
tly teased away from the cell suspension, agitated for 10 min, and placed on 
ice. The cell suspension was filtered successively through 100-μm, 40-μm, 
and 20-μm nylon gauze and centrifuged for 8 min at 130 g. After centrifu-
gation, cells were resuspended in complete DMEM (containing 20 mM 
HEPES, 10% FBS, and 100 U/ml penicillin-streptomycin). Cells were then 
incubated on precoated dishes containing 45 μg/ml anti-mouse CD45 and 
16 μg/ml anti-mouse CD32 for 2 h in a tissue culture incubator (5% CO2 
at 37°C). Nonadherent cells were panned from the antibody plates, rinsed 
with complete DMEM, centrifuged, and resuspended in complete DMEM. 
The cells were then placed in 6-well plates precoated with a mixture of 80% 
Matrigel (BD Biosciences) and 20% complete DMEM. Cell purity was deter-
mined by light microscopy. Cells were maintained in complete DMEM.
CSE and treatment. CSE was generated by bubbling smoke from 1 standard 
reference cigarette into 10 ml PBS through a 50-ml fritted impinger at a flow 
rate of 350 ml/min. The resulting extract was passed through a 0.22-mm 
filter and was considered 100% CSE. The CSE was adjusted to pH 7.4 by 
the addition of NaOH before addition to the epithelial cell cultures. CSE 
treatment was performed in 6-well plates, and experiments were performed 
using cells at approximately 80% confluence. Briefly, cells were replenished 
with fresh media, allowed to equilibrate for 2 h (5% CO2 at 37°C), and 
exposed to CSE or PBS for 24 h. Cells were released from the Matrigel with 
Matrisperse (BD Biosciences) nonenzymatic recovery solution according 
to the manufacturer’s instructions in order to ensure minimal distress to 
the cell surface ligands. RAET1 expression on the surface of epithelial cells 
was determined by staining with the anti-RAET1α−RAET1e monoclonal 
antibody (clone 186107; R&D Systems). Flow cytometry was performed on 
a FACScan cytofluorometer (BD), and data acquisition and analysis was 
performed using CellQuest Pro software (version 5.2; BD).
Preparation of mouse lymphocytes and cytotoxicity assays. Lymphocytes were 
isolated and purified from mouse spleen using a magnetic cell separation 
system according to the manufacturer’s protocol (Miltenyi Biotech). The 
protocol uses a negative selection strategy to magnetically retain antibody-
bound granulocytes. The effluent from this protocol yields untouched, 
enriched lymphocytes. A recovery of approximately 40% lymphocytes per 
spleen was typical. Approximately 20% of splenic lymphocytes express 
NKG2D upon isolation, and do so for up to 12 d when maintained in 
RPMI-1640 containing 1,000 U/ml recombinant human IL-2. All coculture 
studies were conducted with freshly isolated cells in RPMI-1640 containing 
1,000 U/ml recombinant human IL-2 and mouse alveolar epithelial cells 
treated with 3% CSE or PBS for 24 h. Cytotoxicity assays were performed 
using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) 
according to the manufacturer’s instructions.
Raet1 Tg mice. Ccsp-rtta transgenic mice, on the FVBN background, were 
previously generated (24), and DOX-inducible Raet1a-expressing mice, 
on the FVBN background, were generated at the University of Cincinnati 
using Raet1a cDNA obtained by PCR cloning as described in Supplemen-
tal Figure 1 and in previous publications (24, 25). DOX was administered 
in the diet (TD.01306 rodent diet, 2,018 diet and 625 mg DOX; Harlan 
Teklad) beginning at 8–10 wk of age.
Morphometric analysis and pulmonary mechanics. The average intra-alveolar 
distance was calculated as the mean linear intercept on H&E-stained sections 
of inflation-fixed (20 cm H2O) mouse lungs, as previously detailed (60). Total 
respiratory system mechanics were assessed in mice using the forced oscilla-
tion technique (FlexiVent; Scireq) according to the method of Gomes (61).
Anti-NKG2D administration. NKG2D receptor function was blocked by i.p. 
administration of the rat anti-mouse NKG2D monoclonal antibody CX5 
(eBioscience) under conditions identical to those previously reported (23).
In vivo lymphocyte depletion. Lymphocyte populations were depleted by 
repeated i.p. administration of antibodies (100–200 μg/mouse, every 
4 d beginning 8 d prior to DOX administration) specific for NK cells 
(anti–asialo GM1; Wako Chemicals USA), αβ T cells (clone H57-97), γδ 
T cells (clone UC7-13D5), CD4+ cells (clone GK1.5), and CD8+ cells (clone 
2.43). All TCR antibodies were kindly provided by G. Deepe (University 
of Cincinnati). Lymphocyte depletion was greater than 90% in all experi-
ments, as confirmed by analyzing peripheral blood cells using the detec-
tion antibodies against the following cell types: NK cells (anti-NKp46, 
clone 29A1.4; eBioscience), αβ T cells (clone 145-2C11; BD Biosciences 
— Pharmingen), γδ T cells (clone GL3; BD Biosciences — Pharmingen), 
CD4 cells (clone LT34; BD Biosciences — Pharmingen), and CD8 cells 
(clone 53-67; BD Biosciences — Pharmingen).
Caspase bioassay. Whole lung homogenates were prepared in PBS, and 
commercially available kits were used to estimate the activity of Casp3/7 
according to manufacturer’s instructions (Apo-ONE Homogenous Cas-
pase-3/7 Assay; Promega).
Quantitative real-time PCR. Total RNA was isolated from mouse lung with 
TRIzol Transcription Kit (Applied Biosystems). For each gene examined, 
quantitative RT-PCR was performed on an ABI 7300 System using pre-
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validated TaqMan Gene Expression Assays Reagent (Invitrogen) and sub-
sequently converted into cDNA using the High Capacity cDNA Reverse 
according to the manufacturer’s standard protocols (Applied Biosystems). 
Gene expression was normalized to the Hprt1 endogenous control gene, 
and relative quantitation of gene expression was calculated using the com-
parative Ct method (2–ΔΔCt).
BAL and cell enumeration. After exposure, mice were anesthetized (50 mg/kg 
of pentobarbital sodium i.p.) and exsanguinated by severing the pos-
terior abdominal aorta. The lungs were then lavaged 2 times with 1 ml 
HBSS. Individual BAL returns were pooled and centrifuged at 300 g for 
10 min. The supernatant was removed and stored at 70°C. The cell pellet 
was reconstituted in 1 ml HBSS containing 2% FBS. Total cell counts were 
determined with a hemocytometer. Differential cell counts (>300 cells) 
were performed on Diff-Quik–stained (Baxter Diagnostics) cytospin slides 
(Cytospin3; Shandon Scientific).
Pulmonary lymphocyte characterization. Single cell suspensions from 
perfused, digested lungs were layered onto a single-step Percoll gradient 
(60% Percoll, ρ = 1.084; 1× HBSS; and 15 mM HEPES, pH 7.4) and centri-
fuged at 2,000 g for 45 min at 4°C. The buffy coat containing mononucle-
ar cells was removed and washed twice in PBS containing 2% FCS. The cell 
pellet was then subject to red blood cell lysis, washed, and resuspended 
in PBS containing 2% FCS. Cells were labeled with antibodies against 
CD3 (clone 145-2C11; BD Biosciences — Pharmingen), TCRδ (clone GL3; 
BD Biosciences — Pharmingen), CD4 (clone GK1.5; BD Biosciences — 
Pharmingen), CD8 (clone 53-6.7; BD Biosciences — Pharmingen), NK1.1 
(clone PK136; BD Biosciences), and NKG2D (clone CX5; eBiosciences). 
Cells were analyzed by flow cytometry using a FACScan cytofluorometer 
(BD). Data acquisition and analysis were performed using CellQuest Pro 
software (version 5.2; BD).
Zymogram. Mice were anesthetized (50 mg/kg of pentobarbital sodium 
i.p.) and exsanguinated by severing the posterior abdominal aorta. Lungs 
were removed, immersed in liquid nitrogen, and homogenized in HBSS. 
Gelatin zymography was performed using whole lung homogenates. Briefly, 
60 μg lung protein in 2× Tris-Glycine gel loading buffer was electropho-
resed at 125 V for 60 min in a 10% Tris-Glycine gel containing 0.1% gelatin 
(Invitrogen). Gels were washed twice in zymogram renaturing solution, pre-
incubated for 30 min at 37°C in zymogram developing solution, and incu-
bated in zymogram developing solution (Invitrogen). Gels were stained with 
0.5% Coomassie blue (Sigma-Aldrich) in 40% methanol and 10% acetic acid 
(1 h, 22°C) and destained in 40% methanol and 10% acetic acid (1 h, 22°C), 
with 2 changes of destaining solution to visualize digested bands in the 
gelatin matrix. A parallel SDS-PAGE gel was loaded with 60 μg protein and 
stained with Coomassie blue as a loading control. Gels were photographed 
using a FOTO/Analyst Investigator System digital camera (Fotodyne).
Human ethics and study design. Bronchial biopsies and surgical specimens 
were collected from 2 separate patient study groups. The Research Com-
mittee of Human Investigation at IMIM approved the study for endoscopic 
biopsy collection from adult patients admitted to the Bronchoscopy Facil-
ity for diagnostic purposes. Written informed consent was obtained from 
each participant. The Institutional Review Board of the University of Cin-
cinnati College of Medicine approved protocols to obtain surgical speci-
mens from patients undergoing thoracic surgery procedures for benign 
and malignant disease.
Patient identification and case enrollment. For both study groups, COPD 
diagnosis was made according to Global Initiative for Obstructive Lung 
Disease criteria (1). All patients undergoing endoscopic bronchial biopsy 
were clinically stable for more than 2 mo. Some patients received regular 
treatment with inhaled bronchodilators (n = 21) and/or inhaled steroids 
(n = 7). Patients were excluded for reasons of COPD exacerbation in the 
last 3 mo, clinical suspicion of bronchial asthma, treatment with systemic 
steroids within the last 2 mo, or tumor observed in the trachea or main 
bronchi during bronchoscopy. Smoking status data was collected via a 
questionnaire. Exhaled CO was measured to confirm smoking cessation 
or continued smoking.
Pulmonary function. For patients undergoing endoscopic bronchial biopsy, 
pulmonary function was assessed by forced spirometry (Datospir 900; SIBEL). 
Static lung volume determination, airway resistance, and TLCO were deter-
mined using plethysmography and single breath analysis (Masterlab; Jaeger). 
Reference values used were those for the Mediterranean population (62).
For patients undergoing thoracoscopic procedures at the University of 
Cincinnati, pulmonary function was tested using the Vmax Encore (Viasys 
Healthcare) according to American Thoracic Society guidelines (63). Refer-
ence values for this population were determined according to Morris (64). 
COPD was diagnosed according to the Global Initiative for Obstructive 
Lung Disease (1). Clinical patient characteristics from the 2 institutions 
were similar in pack years, pulmonary function parameters, and tumor 
incidence. See Table 1 and Supplemental Tables 1–3 for complete demo-
graphic and clinical characteristics of both patient groups.
CT of the lungs. CT of the lungs was available in 76 (93%) of the selected 
study subjects. All CT scans were taken in the supine position with 1.25 
and 7 mm collimation, scanning time of 0.75 s, 120 kV, and 90 mAs 
(SOMATOM Sensation 4; Siemens). Images were reconstructed using high 
(B70) and low (B40) spatial frequency resolution algorithms for all cases. 
The machines were calibrated with standard protocols every 6 mo using the 
manufacturers’ standard phantom and yearly, according to the national 
regulatory guidelines. Scans were obtained at full inspiration, and no i.v. 
contrast was used. Scans were independently examined for the presence of 
emphysema by radiologists blinded to the subjects’ clinical history. The 
radiological diagnosis of emphysema was made if centrilobular low-density 
areas or panlobular or paraseptal emphysematous changes were present, 
and subjects were graded as having no evidence of emphysema, changes 
suggestive of emphysema, or definite emphysema. In cases of discordance, 
the images were viewed together and a consensus decision reached. Only 
subjects with definite emphysema were included as having macroscopic 
disease in subsequent analyses (42).
Bronchoscopy, bronchial biopsies, and surgical specimen collection. Endo-
bronchial biopsy specimens were obtained by direct visualization using 
a flexible videobronchoscope (BF-200; Olympus) and bronchial biopsy 
forceps (FB 21-C; Olympus) from macroscopically normal areas of the 
third order carina as previously described (65). Biopsies were preserved 
in formalin and fixed in paraffin. Surgical specimens were obtained from 
patients who underwent pulmonary resections for benign and malignant 
processes. Surgical specimens were obtained from lung tissue distant 
from the tumor site and were cut by a certified pathologist within the 
Anatomic Pathology Department, University of Cincinnati Hospital. Por-
tions of the surgical specimens were snap frozen in liquid nitrogen and 
subsequently stored at –80°C until protein extraction. In some patients, 
portions were immediately placed in cell culture media and enzymatically 
digested as described below.
Immunoblots. Protein isolation and immunoblot analyses were per-
formed as previously described (22). Membranes were incubated overnight 
with anti-MICA (catalog no. AF1300; R&D Systems) or anti–granzyme B 
(clone 216315; R&D Systems), then incubated with IgG-HRP–conjugated 
secondary antibody and detected by chemiluminescence (ECL Reagents; 
Amersham). Membranes were stripped and reprobed with anti-GAPDH 
or anti–β-actin antibodies (Santa Cruz Biotechnology Inc.). Individual 
MICA and β-actin bands were quantitated by scanning densitometry using 
ImageQuant software (version 5.2; Molecular Dynamics).
Human lung cell isolation and flow cytometry. Freshly isolated lung tissue 
(~1.0 g) obtained from patients undergoing surgical resections was diced 
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into pieces of less than 500 μl in 4 ml HBSS containing 175 U/ml col-
lagenase, 0.2 U/ml pancreatic elastase, 35 U/ml hyaluronidase, 20 KU/ml 
DNAse (Sigma-Aldrich), 10% FCS, 100 U/ml penicillin, and 100 μg/ml 
streptomycin (CellGro) and incubated for 30 min at 37°C on an orbital 
shaker. Digested tissue was sheared through a 20-gauge needle and passed 
through 40-μm filters. Leukocytes were recovered by layering over a 30% 
Percoll solution and centrifuging at 400 g for 40 min. Identification of 
CD3+ (anti-human CD3, clone SK7, PerCP-C5.5 conjugated; BD Biosci-
ences), CD4+ (anti-human CD4, clone RPA-T4, FITC conjugated; BD 
Biosciences), CD8+ (anti-human CD8, clone HIT8a, PE conjugated; BD 
Biosciences), NK (anti-human CD56, clone B159, APC conjugated; BD 
Biosciences), and NKG2D+ (anti-human NKG2D, clone 1D11, APC conju-
gated; BD Biosciences) cell populations was determined by flow cytometry 
using a FACSCalibur cytofluorometer (BD). Data acquisition and analysis 
was performed using CellQuest Pro software (version 5.2; BD).
Statistics. Animal data were analyzed for normality using SigmaStat soft-
ware (version 3.5; Systat Software). Significant differences among groups 
were identified by ANOVA, and individual comparisons between groups 
were confirmed by a post-hoc Tukey test, with differences between means 
considered significant at P < 0.05. All data presented are mean ± SD. The 
relationship between RAET1 and alveolar diameter in mouse models was 
assessed by an exponential rise, 2 parameter nonlinear regression analysis 
(y = a[1 – e–bx]) performed using SigmaStat software.
Clinical characteristics are expressed as mean and SD or as a percent-
age. MICA frequency comparison between different groups was performed 
by χ2 test. Mean values of pulmonary function variables were compared 
using 2-tailed Student’s t test between MICA+ and MICA– patients. Risk 
estimates were assessed by logistic regression. A P value of less than 0.05 
was considered significant. Clinical statistics were performed using Stata 
(release 8.0; StataCorp).
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